Novo Nordisk stock plunges 42% so far in 2025 as GLP-1 competition, price cuts, guidance trims and restructuring plans cloud ...

A perfect storm of clinical setbacks, intensifying competition, and internal upheaval has triggered a historic sell-off in ...

The coming year, 2026, is shaping up as a critical operational and financial test. A head-to-head comparative study between Novo Nordisk's CagriSema and Eli Lilly's Zepbound, scheduled for 2026, will ...

The slump has virtually wiped out several years of stellar gains that came after Novo’s Wegovy drug was approved as a ...

Pfizer bets on YaoPharma’s oral GLP-1 pill YP05002 after past failures, aiming to rejoin the booming $150B obesity-drug market.

Novo Nordisk (NYSE: NVO) stock was slimming down on Monday, but not in the way any investor in the Wegovy and Ozempic ...

Structure Therapeutics stock soars 103% as its oral obesity drug aleniglipron shows strong Phase 2b weight-loss results.

Amid an outpouring of obesity data Monday, Wave Life Sciences and Structure Therapeutics were among the biotechs jockeying to ...

In November, Mounjaro clocked Rs 108 crore in sales, making it the number 1 brand in the IPM, reflecting sustained momentum ...

The pharmaceutical giant Novo Nordisk is navigating a complex week, confronting issues in two major markets that highlight ...

Novo Nordisk A/S acquires Zaltenibart for $2.1B, targeting rare diseases. NVO shares present a de-risked entry point. Click for this updated look at NVO stock.

A promising obesity and diabetes drug stumbles in Alzheimer's trials, rattling markets. Did investors overreact, or is this a ...